This meeting took place in 2019

Here are the related meetings in 2020:
Microbiome: Therapeutic Implications (T1)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Host and the Environment in IBD: Scientific Advances Leading to New Therapeutics (A2)

Organizer(s) Gary D. Wu, Scott Snapper, Judy H. Cho and Aida Habtezion
January 13—17, 2019
Sagebrush Inn & Suites • Taos, New Mexico USA
Discounted Abstract Deadline: Oct 4, 2018
Abstract Deadline: Oct 16, 2018
Scholarship Deadline: Oct 4, 2018
Discounted Registration Deadline: Nov 13, 2018

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., Janssen R&D: Pharmaceutical Companies of Johnson & Johnson, Takeda Pharmaceutical Company Limited and Theravance Biopharma

Summary of Meeting:
Inflammatory bowel diseases (IBD), which afflict millions of patients, are rapidly increasing in incidence world-wide in parallel with industrialization. Pathogenesis involves both host genetic as well environmental factors, with the most currently utilized therapeutics focusing on long-term host immunosuppression. Despite tremendous advances in our understanding of IBD genetics, the mucosal immune system, and environmental factors such as the gut microbiome, currently available therapeutic modalities for IBD remain suboptimal. The overall goal of this conference is to bring together world-class investigators and clinicians to discuss the latest scientific knowledge relevant to the pathogenesis of IBD and facilitate an interactive discussion to accelerate development of new opportunities to prevent and/or treat IBD. The specific aims of this conference are to: 1) Bring together a combination of clinical and basic investigators from both academia and industry to facilitate cross-disciplinary discussions focused on IBD; 2) Identify both opportunities and gaps in current knowledge of the pathogenesis of IBD important for the development of new diagnostics and therapeutics; and 3) Create a multidisciplinary environment that will inspire both young and established investigators by highlighting currently available opportunities in IBD research. The anticipated outcome will be a better understanding of the advances and challenges in developing new therapies for patients with IBD.

View Meeting Program


National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Scholarship Recipients

Dominic Boardman
University of British Columbia, Canada

Rafael Sanguinetti Czepielewski
Washington University in St. Louis, USA

Daniel A. Giles
La Jolla Institute for Allergy and Immunology, USA

Samantha Hsieh
Washington University School of Medicine, USA

June-Yong Lee
New York University School of Medicine, USA

Angela Mo
Georgia Institute of Technology, USA

Vu Ngo
Georgia State University, USA

Samuel Rubin
Stanford University School of Medicine, USA